Plumestars attended the 2017 AAPS Annual Meeting & Exposition in San Diego presenting a poster on the last orphan medicine getting the EMA and FDA orphan designation. The orphan medicine presented was the powder of thalidomide prepared for both the oral and nasal administration.

The objective was to counteract the nasal epistaxis in term of frequency, intensity and duration. The therapy plan was to start with the administration of the oral capsule reaching a significant reduction of the nose  bleeding and continuing until the appearance of important adverse effects.

Then, the nasal thalidomide powder was administered directly on the nasal cavity to maintain the benefit obtained orally and decreasing the systemic exposition.